Patients receiving curative intent, HER2-directed therapy, are commonly monitored with serial echocardiograms every 3 months as trastuzumab can cause reversible cardiomyopathy and a drop in left ventricular ejection fraction (20). The gene discussed is ERBB2; the disease is cardiomyopathy.